187 related articles for article (PubMed ID: 35790147)
1. Torsade de Pointes/QT Prolongation Associated with Antifungal Triazoles: A Pharmacovigilance Study Based on the U.S. FDA Adverse Event Reporting System（FAERS）.
Yu Z; Liao X
J Pharm Pharm Sci; 2022; 25():237-243. PubMed ID: 35790147
[TBL] [Abstract][Full Text] [Related]
2. Association of Torsade de Pointes and QT Prolongation With Antifungal Triazoles: Analysis Using a Pharmacovigilance Database.
Ohyama K; Akiyama S; Iida M; Hori Y
In Vivo; 2023; 37(6):2719-2725. PubMed ID: 37905641
[TBL] [Abstract][Full Text] [Related]
3. Association of H1-antihistamines with torsade de pointes: a pharmacovigilance study of the food and drug administration adverse event reporting system.
Ali Z; Ismail M; Khan F; Sajid H
Expert Opin Drug Saf; 2021 Jan; 20(1):101-107. PubMed ID: 33141610
[No Abstract] [Full Text] [Related]
4. Drug-induced QT prolongation and torsade de pointes: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database.
Li D; Chai S; Wang H; Dong J; Qin C; Du D; Wang Y; Du Q; Liu S
Front Pharmacol; 2023; 14():1259611. PubMed ID: 38186652
[No Abstract] [Full Text] [Related]
5. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine.
Sarayani A; Cicali B; Henriksen CH; Brown JD
Res Social Adm Pharm; 2021 Feb; 17(2):483-486. PubMed ID: 32327397
[TBL] [Abstract][Full Text] [Related]
6. Torsades de pointes and QT prolongation Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System.
Teng C; Walter EA; Gaspar DKS; Obodozie-Ofoegbu OO; Frei CR
Int J Med Sci; 2019; 16(7):1018-1022. PubMed ID: 31341415
[No Abstract] [Full Text] [Related]
7. Torsade de pointes associated with chloroquine, hydroxychloroquine, and azithromycin: a retrospective analysis of individual case safety reports from VigiBase.
Saint-Gerons DM; Tabarés-Seisdedos R
Eur J Clin Pharmacol; 2021 Oct; 77(10):1513-1521. PubMed ID: 33938974
[TBL] [Abstract][Full Text] [Related]
8. Drug-induced torsades de pointes: Disproportionality analysis of the United States Food and Drug Administration adverse event reporting system.
Wu Z; Zhou P; He N; Zhai S
Front Cardiovasc Med; 2022; 9():966331. PubMed ID: 36352852
[TBL] [Abstract][Full Text] [Related]
9. Linezolid and the risk of QT interval prolongation: A pharmacovigilance study of the Food and Drug Administration Adverse Event Reporting System.
Shao H; Shi D; Dai Y
Br J Clin Pharmacol; 2023 Apr; 89(4):1386-1392. PubMed ID: 36346345
[TBL] [Abstract][Full Text] [Related]
10. Cholinesterase inhibitors-associated torsade de pointes/QT prolongation: a real-world pharmacovigilance study.
Zhang N; Gan L; Xiang G; Xu J; Jiang T; Li Y; Wu Y; Ni R; Liu Y
Front Pharmacol; 2023; 14():1343650. PubMed ID: 38273821
[No Abstract] [Full Text] [Related]
11. A real-world pharmacovigilance study of QT interval prolongation and Torsades de Pointes associated with CDK4/6 inhibitors in breast cancer patients: findings from the FDA adverse event reporting system.
Yan Y; Wu B; Wang L
Expert Opin Drug Saf; 2024 Mar; ():1-8. PubMed ID: 38482864
[TBL] [Abstract][Full Text] [Related]
12. Clinical characterization of men with long QT syndrome and torsades de pointes associated with hypogonadism: A review and pharmacovigilance study.
Salem JE; Bretagne M; Lebrun-Vignes B; Waintraub X; Gandjbakhch E; Hidden-Lucet F; Gougis P; Bachelot A; Funck-Brentano C;
Arch Cardiovasc Dis; 2019 Nov; 112(11):699-712. PubMed ID: 31477476
[TBL] [Abstract][Full Text] [Related]
13. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system.
Pearson EC; Woosley RL
Pharmacoepidemiol Drug Saf; 2005 Nov; 14(11):747-53. PubMed ID: 15918160
[TBL] [Abstract][Full Text] [Related]
14. Voriconazole-induced QT interval prolongation and torsades de pointes.
Aypar E; Kendirli T; Tutar E; Çiftçi E; Ince E; Ileri T; Atalay S
Pediatr Int; 2011 Oct; 53(5):761-763. PubMed ID: 21955009
[No Abstract] [Full Text] [Related]
15. Gastrointestinal perforation associated with novel antineoplastic agents: A real-world study based on the FDA Adverse Event Reporting System.
Yu Z; Zhu H; Chen H; Zhu L; Liao X
J Pharm Pharm Sci; 2023; 26():11235. PubMed ID: 36942297
[No Abstract] [Full Text] [Related]
16. Epidemiology of symptomatic drug-induced long QT syndrome and Torsade de Pointes in Germany.
Sarganas G; Garbe E; Klimpel A; Hering RC; Bronder E; Haverkamp W
Europace; 2014 Jan; 16(1):101-8. PubMed ID: 23833046
[TBL] [Abstract][Full Text] [Related]
17. An Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval.
Lorberbaum T; Sampson KJ; Woosley RL; Kass RS; Tatonetti NP
Drug Saf; 2016 May; 39(5):433-41. PubMed ID: 26860921
[TBL] [Abstract][Full Text] [Related]
18. OTc prolongation and torsade de pointes ventricular tachycardia in a small dose voriconazole therapy.
Elbey MA; Cil H; Onturk E; Islamoglu Y
Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):100-2. PubMed ID: 22338554
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial-associated QT interval prolongation: pointes of interest.
Owens RC; Nolin TD
Clin Infect Dis; 2006 Dec; 43(12):1603-11. PubMed ID: 17109296
[TBL] [Abstract][Full Text] [Related]
20. A pharmacovigilance study to quantify the strength of association between the combination of antimalarial drugs and azithromycin and cardiac arrhythmias: implications for the treatment of COVID-19.
Diaby V; Almutairi RD; Chen Z; Moussa RK; Berthe A
Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):159-168. PubMed ID: 33186061
[No Abstract] [Full Text] [Related]
[Next] [New Search]
